Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches.
Inflammation is the body's defense mechanism against threats such as bacterial infection, undesirable substances, injury, or illness. The process is complex and involves a variety of specialized cells that mobilize to neutralize and dispose of the injurious material so that the body can heal. In the brain, a similar inflammation process occurs when glia, especially astrocytes and microglia, undergo activation in response to stimuli such as injury, illness, or infection. Like peripheral immune cells, glia in the central nervous system also increase production of inflammatory cytokines and neutralize the threat to the brain. This brain inflammation, or neuroinflammation, is generally beneficial and allows the brain to respond to changes in its environment and dispose of damaged tissue or undesirable substances. Unfortunately, this beneficial process sometimes gets out of balance and the neuroinflammatory process persists, even when the inflammation-provoking stimulus is eliminated. Uncontrolled chronic neuroinflammation is now known to play a key role in the progression of damage in a number of neurodegenerative diseases. Thus, overproduction of proinflammatory cytokines offers a pathophysiology progression mechanism that can be targeted in new therapeutic development for multiple neurodegenerative diseases. We summarize in this chapter the evidence supporting proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative disorders, with a focus on Alzheimer's disease. In addition, we discuss the drug discovery process and two approaches, function-driven and target-based, that show promise for development of neuroinflammation-targeted, disease-modifying therapeutics for multiple neurodegenerative disorders.
Van Eldik
Linda J
LJ
Center for Drug Discovery and Chemical Biology, Northwestern University Chicago, Illinois 60611, USA.
Thompson
Wendy L
WL
Ralay Ranaivo
Hantamalala
H
Behanna
Heather A
HA
Martin Watterson
D
D
D000544:Alzheimer Disease / Q000473:pathology / Q000503:physiopathology; D000818:Animals; D016207:Cytokines / Q000502:physiology*; D016503:Drug Delivery Systems; D006801:Humans; D018836:Inflammation Mediators / Q000502:physiology*; D019636:Neurodegenerative Diseases / Q000188:drug therapy* / Q000503:physiopathology*; D009457:Neuroglia / Q000187:drug effects* / Q000502:physiology*; D010766:Phosphorylation; D015398:Signal Transduction / Q000502:physiology; D015854:Up-Regulation / Q000187:drug effects; D048051:p38 Mitogen-Activated Protein Kinases / Q000502:physiology
D016207:Cytokines; D018836:Inflammation Mediators; D048051:p38 Mitogen-Activated Protein Kinases